Baxter International stock

BAX · NYSE · USD

Compare Baxter International
$25.39Change from previous close: 0.00%Absolute change: +$0.00

Close · November 20, 2026

Price history

+45.75% over the period

1 year: from $17.42 (November 20, 2025) to $25.39 (November 20, 2026), +45.75%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026$25.39
October 30, 2026$23.00
September 30, 2026$24.00
August 31, 2026$26.00
July 31, 2026$26.16
June 30, 2026$21.32
May 29, 2026$18.78
April 30, 2026$17.58
March 31, 2026$16.80
February 27, 2026$20.37
January 30, 2026$20.07
December 31, 2025$19.11
November 28, 2025$18.74
November 20, 2025$17.42

At a glance

  • The company

    Provides sterile IV solutions, infusion systems, parenteral nutrition, anesthetics, surgical equipment, patient monitoring technologies and respiratory health devices for hospitals and home care

  • Latest results

    Quarter to September 30, 2026 · EPS $0.58 (estimate $0.52)

TickerLandia's take on Baxter International

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$15.73
52-wk high$30.00

−15.37% from the 52-week high

Analysts · 15 analysts

Average target$27.25+7.33% vs. price

Buy 2 · Hold 12 · Sell 1 · Hold

TickerLandia Fingerprint: Baxter International

Compared with similar companies: very low earnings stability, very low profitability, and very low price.

Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 888 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Baxter International is cheaper than similar companies

Baxter International's Forward P/E: 12.4, −26% against the median of a group of 11 similar companies (16.7).

Compared with 11 similar companies

Baxter International's metrics compared with similar companies
MetricBaxter InternationalPosition in the groupBand
Forward P/E12.4Low
Operating margin7.6%Low
ROE-9.0%Low
Debt/equity1.36High
Price/book2.02Low

Grey band: the middle half of the group; tick: the median; dot: Baxter International. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$2.98B

Latest quarter · Q3 2026

Net income

$294M

Latest quarter · Q3 2026

Quarterly net margin

9.9%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$13.14B
EPS
-$1.21
Volume
4.32M
Daily trading
€160.77M
Dividend yield
0.16%

How Baxter International is changing

All results
  • Revenue fell 0.7% a year on average over the last 5 years

  • Operating margin rose from −28.3% to −2.7%

  • Revenue has grown for 3 fiscal years in a row

Returns

Baxter International returns with dividends

$1,000 invested in Baxter International 5 years ago, on November 22, 2021, would be worth $353 today with dividends reinvested: −64.66% in total, −18.80% per year. On price alone it would be $320 (−67.96%).

PeriodBaxter InternationalS&P 500$1,000 becomes
1 month+3.59%−10.40%$1,036
6 months+35.27%−7.03%$1,353
Year to date+32.86%+0.95%$1,329
1 year+46.03%+5.68%$1,460
3 years−24.66%+51.96%$753
5 years−64.66%+47.57%$353
10 years−37.08%+214.37%$629

Over the last 6 months it has done better than 84% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Baxter International: technical analysis

Baxter International is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 73.0% below its highest close since January 2, 1990 ($94.14, April 20, 2020).

Trend
Upward
RSI (14 sessions)
50
Between 30 and 70
vs 200-session average
+16.64%

Support and resistance

Price areas where Baxter International has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$25.87+1.89%2 touches, last on October 16, 2026
  2. Last price$25.39
  3. Support$23.62−6.97%3 touches, last on October 20, 2026
  4. Support$22.49−11.42%3 touches, last on October 30, 2026
  5. Support$21.28−16.20%4 touches, last on July 23, 2026

Volatility and risk

Over the last year it has moved roughly in line with the S&P 500.

Beta (1 year) vs S&P 500
1.00
Volatility (60 sessions, annualised)
35.3%
Largest fall in the last year
−29.05%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Baxter International: seasonality

Average monthly price change over 37 years

+2.5%Jan+0.2%Feb+0.2%Mar+1.0%Apr+1.0%May+0.5%Jun+2.2%Jul+0.1%Aug−1.6%Sep−2.9%Oct+2.6%Nov+1.1%Dec

Over the last 37 years, the strongest month for Baxter International has been November: +2.58% on average, positive in 24 years out of 36. The weakest has been October: −2.86% on average, positive in 15 years out of 37.

Show chart data
MonthAverageMedianPositive years
January+2.54%+1.73%21 of 36
February+0.20%+0.70%20 of 37
March+0.21%+1.53%22 of 37
April+0.97%+1.10%21 of 37
May+1.02%+0.66%22 of 37
June+0.55%+0.54%20 of 37
July+2.23%+5.44%24 of 37
August+0.11%+0.80%21 of 37
September−1.58%−0.55%18 of 37
October−2.86%−2.27%15 of 37
November+2.58%+2.50%24 of 36
December+1.11%+1.32%22 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Baxter International and its competitors

Sterile intravenous solutions, infusion systems and parenteral nutrition therapies are among the products hospitals and patients associate with Baxter. The company also makes surgical hemostat and sealant products, smart bed systems, patient monitoring devices, inhaled anesthetics and generic injectable pharmaceuticals, organized in three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. Its products reach hospitals, nursing homes, dialysis centers, ambulatory surgery centers and patients at home, sold through a direct sales force, independent distributors and drug wholesalers.

Headquarters
Deerfield, United States
Employees
37,500
Founded
1931
Chief executive
Andrew Hider
Baxter International and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Baxter InternationalBAX$13.14B7.6%—+35.27%
SolventumSOLV$14.36B5.9%94.9+10.99%
Cooper CompaniesCOO$11.2B12.9%20.2−4.65%
Align TechnologyALGN$10.94B19.6%22.6−5.03%
RepligenRGEN$10.89B8.1%—+46.60%
AvantorAVTR$10.06B8.0%29.7+88.32%

Same industry or related industries, similar size. Compare Baxter International with its competitors · Full profile